ImageIQ formally announced a Memorandum of Understanding (MOU) with T3 Labs, an Atlanta-based provider of biomedical preclinical testing and training services, to enhance and accelerate preclinical research and development through the use of quantitative imaging and image analysis. The two organizations have been successfully working together for the better part of two years.
The collaboration will combined T3 Labs’ expertise in preclinical study design and execution with ImageIQ’s unique blend of imaging expertise and software-based quantitative image analysis and data reporting. Together, the collaborators will custom-tailor their services and technology to fit to the needs of each study they support. The overarching goal of the collaboration will be to leverage quantitative imaging and image analysis to accelerate biomedical product testing, regulatory approval and commercialization through better science and stronger, more objective data.
As a result, medical device, biologic and drug companies will have access to a comprehensive single source of preclinical expertise and services spanning study design to animal husbandry to surgical procedures to multi-modal image acquisition, analysis and data reporting.
“T3 Labs is delighted to strategically align with ImageIQ,” said Dr. Evan Goldberg, T3 Labs Program Director. “Our past success with ImageIQ made this an easy decision for us to make. We are committed to being on the forefront of the changing technology and methodology paradigms in preclinical research and development, and thereby delivering sustained value to our clients by leveraging ImageIQ’s expertise and technology.”
“This collaboration is strategically important to us for our preclinical research market, and we are pleased to have T3 Labs as a partner,” said Tim Kulbago, ImageIQ CEO. “Their expertise in designing and executing preclinical studies perfectly aligns with ours in preclinical imaging and image analysis, and their cultural obsession with customer service made it an ideal fit.”